Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application
Authors
Keywords
-
Journal
Gastroenterology Research and Practice
Volume 2016, Issue -, Pages 1-9
Publisher
Hindawi Limited
Online
2016-01-11
DOI
10.1155/2016/4105615
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- FDA Approval Summary: Ramucirumab for Gastric Cancer
- (2015) S. J. Casak et al. CLINICAL CANCER RESEARCH
- Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
- (2015) Sylvie Lorenzen et al. EUROPEAN JOURNAL OF CANCER
- Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
- (2015) Min-Hee Ryu et al. EUROPEAN JOURNAL OF CANCER
- Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
- (2015) Hung Huynh et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Molecular Biomarkers in Gastric Cancer
- (2015) Elena Elimova et al. Journal of the National Comprehensive Cancer Network
- S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer
- (2015) Feng Du et al. MEDICINE
- Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
- (2015) Christopher D. Hart et al. Nature Reviews Clinical Oncology
- Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
- (2014) Y Kurokawa et al. BRITISH JOURNAL OF CANCER
- Ramucirumab: First Global Approval
- (2014) Raewyn M. Poole et al. DRUGS
- Apatinib for the treatment of gastric cancer
- (2014) Ruixuan Geng et al. EXPERT OPINION ON PHARMACOTHERAPY
- Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer
- (2014) Do Joong Park et al. Gastric Cancer
- Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
- (2014) Taroh Satoh et al. Gastric Cancer
- Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
- (2014) Lin Shen et al. Gastric Cancer
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the HGF/MET pathway in gastric cancer
- (2014) Florian Lordick LANCET ONCOLOGY
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
- (2013) N C T van Grieken et al. BRITISH JOURNAL OF CANCER
- Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
- (2013) EUROPEAN JOURNAL OF CANCER
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
- (2013) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- (2013) Manish A. Shah et al. PLoS One
- New agents in renal cell carcinoma
- (2013) Raetasha Dabney et al. Targeted Oncology
- Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer
- (2013) Jiang Liu et al. OncoTargets and Therapy
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
- (2011) Akira Sawaki et al. Gastric Cancer
- mTOR as a therapeutic target in patients with gastric cancer
- (2011) Salah-Eddin Al-Batran et al. INTERNATIONAL JOURNAL OF CANCER
- Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks
- (2011) Yu Kataoka et al. INVESTIGATIONAL NEW DRUGS
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the human EGFR family in esophagogastric cancer
- (2011) Alicia Okines et al. Nature Reviews Clinical Oncology
- Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
- (2010) Z. A. Wainberg et al. CLINICAL CANCER RESEARCH
- Trastuzumab
- (2010) Jamie D. Croxtall et al. DRUGS
- Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
- (2010) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation